Result of AGM

RNS Number : 1112Z

IXICO plc

20 January 2022

 

20 January 2022

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	% ISC VOTED	VOTES WITHHELD
1	Reports and Accounts	30,181,599	99.99	800	0.01	30,184,099	62.69	1,700
2a	Re-election of Charles Spicer	30,166,631	99.97	10,107	0.03	30,184,099	62.69	7,361
2b	Re-election of Grant Nash	30,166,931	99.97	9,807	0.03	30,184,099	62.69	7,361
3	Re-appointment of Auditors	29,764,948	98.66	405,081	1.34	30,184,099	62.69	14,070
4	Allotment of Securities	30,172,562	99.97	10,037	0.03	30,184,099	62.69	1,500
5	* Disapply Pre-Emption Provisions	30,149,112	99.89	33,487	0.11	30,184,099	62.69	1,500

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution. 

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson ( Sales)
Walbrook PR Ltd	[phone]
Paul McManus /  Lianne Applegarth /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on   www.IXICO.com   and follow us on Twitter @IxicOplc

 

END

 

 

RAGBKKBQKBKDADB